IFNB1 and myeloid sarcoma: In vitro, fingolimod reduces the production of MVs derived from cultured monocytes purified from RR‐MS patients, compared to non‐treated MS patients and healthy controls, as well as compared to patients treated with two other first‐line drugs for RRMS (i.e., IFN‐β and teriflunomide).69